10-Q: SS Innovations International Reports Increased Revenue and Reduced Net Loss in Q1 2025

SS Innovations International saw revenue climb and net losses shrink in the first quarter of 2025, driven by increased system and instrument sales.

Summary

• SS Innovations International, Inc. reported its financial results for the quarter ended March 31, 2025.
• The company's revenue increased to $5.12 million, compared to $3.64 million in the same period last year.
• This growth was primarily driven by higher system sales (8 units vs 5 units) and instrument sales.
• The net loss decreased to $5.68 million, compared to $9.84 million in the first quarter of 2024.
• The company's gross profit increased to $1.09 million from $0.73 million.
• Operating expenses totaled $7.01 million, down from $10.56 million year-over-year.
• The company is focused on designing, manufacturing, and marketing its SSi Mantra surgical robotic system.
• The company had a working capital surplus of $32.6 million as of March 31, 2025.
• The company's existing cash resources and income from operations are not expected to provide sufficient funds to carry out the company's operations and business development through the next twelve months.
• The management of the company is making efforts to raise further funding to scale up operations and meet its longer-term capital needs.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, there is significant revenue growth and a reduction in net loss. The successful capital raise is also a positive sign, but the dependence on related-party funding and material weaknesses in internal controls are concerning.

Positives

• Revenue increased by approximately 40% year-over-year.
• Net loss decreased significantly due to lower stock compensation expenses.
• Gross profit increased, indicating improved operational efficiency.
• The company successfully raised $28 million in funding from an affiliate.
• The company converted $30 million in principal amount of One-Year Notes, together with $164,548 in interest thereon, were converted by Sushruta into 21,858,368 shares of our common stock.

Negatives

• The company continues to operate at a net loss.
• The company's existing cash resources and income from operations are not expected to provide sufficient funds to carry out the company's operations and business development through the next twelve months.
• The company is dependent on related parties to fund operations.
• The company's auditors and the audit committee of the Registrants board of directors (or persons performing the equivalent functions) were notified of all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrants ability to record, process, summarize and report financial information.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• There is no assurance that the company will be able to secure additional funding.
• The company faces risks related to obtaining regulatory approvals in various regulated markets.
• The company has material weaknesses in internal control over financial reporting.
• The company is involved in legal proceedings regarding a dispute over shares of Otto Pvt Ltd.

Future Outlook

The company plans to raise additional capital through further private or public offerings in 2025 to scale up operations and fund research and development.

Management Comments

• The company's financial performance is largely driven by increasing awareness of the benefits of robotically assisted surgery, reduced learning curves for robotic surgeons and the affordability and accessibility of surgical robotic technology.
• Our financial performance is also dependent on our obtaining regulatory approvals in various regulated markets where we have plans to sell our products.

Industry Context

The company operates in the growing surgical robotics market, which is driven by technological advancements, increasing adoption of minimally invasive surgeries, and an aging population.

Comparison to Industry Standards

• Intuitive Surgical, a leader in the surgical robotics market, reported revenue of $1.93 billion in Q1 2024, demonstrating the scale of the established players.
• Stryker, another major player, has also invested heavily in robotic surgery, indicating the industry's growth potential.
• Medtronic has made significant investments in surgical robotics, reflecting the increasing importance of this technology in the medical device industry.
• Globally the surgical robotics market is expected to reach $13 billion by 2025.

Legal Proceedings

• The company is involved in litigation in the Bahamas regarding a dispute over shares of Otto Pvt Ltd.
• Dr. Srivastava has agreed to indemnify the company for any claims, damages, and costs related to this litigation.

Related Party Transactions

• The company raised $28 million from Sushruta Pvt Ltd., an affiliate of Dr. Sudhir Prem Srivastava, through convertible promissory notes.
• The company had various expense and consultancy transactions with related parties, including Dr. Sudhir Prem Srivastava, Anup Sethi, and Barry F. Cohen.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises.
• Employees may be affected by the company's ability to secure funding and continue operations.
• Customers may benefit from the company's continued development of surgical robotic systems.
• Suppliers and creditors face risks related to the company's financial stability.

Next Steps

• The company plans to scale up operations and continue research and development.
• The company intends to seek regulatory approvals in various markets.
• The company will work to remediate material weaknesses in internal control over financial reporting.

Key Dates

Keywords

surgical robotics, SSi Mantra, financial results, revenue, net loss, convertible notes, stock compensation, robotic surgery, SS Innovations, funding